US 8,148,330 B2 · Modulation of synaptic maintenance

Abstract

C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.

Claims1

Dependent claims

A method of maintaining neuronal function in a patient with glaucoma, comprising the step of:

administering a therapeutic amount of C1 inhibitor protein to a patient suffering from glaucoma to maintain neuronal function.

Dependencies are inferred from the claim text.

Facts

Application

11/636,001Filed 8 Dec 2006 · us provisional application

Priority

9 Dec 2005

Published

US 2007/0135753 A114 Jun 2007

Granted

3 Apr 2012

Term ends

Not estimatedThe source records don’t support an estimate.

Classification23 codes

G01N 33/5058
Involving specific cell types: neurological cells
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 31/727
Glycosaminoglycans, i.e. mucopolysaccharides: heparin; Heparan
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Modulation of synaptic maintenance

Life of this patent

Abstract

Claims1

Modulation of synaptic maintenance

Life of this patent

Abstract

Claims1